Tandem Diabetes Care Files 8-K

TL;DR

Tandem Diabetes Care filed an 8-K on May 10, 2024, detailing material agreements and other corporate events.

AI Summary

On May 10, 2024, Tandem Diabetes Care, Inc. entered into a Material Definitive Agreement. The filing also includes other events and financial statements/exhibits. The company is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This 8-K filing indicates significant corporate events and the release of financial information for Tandem Diabetes Care, Inc.

Risk Assessment

Risk Level: low — This filing is a standard 8-K report detailing corporate events and financial statements, not indicating immediate financial distress or significant new risks.

Key Numbers

• 12400 High Bluff Drive — Business Address (Principal executive offices location)
• 92130 — ZIP Code (Principal executive offices ZIP code)
• 858-366-6900 — Phone Number (Registrant's telephone number)

Key Players & Entities

• Tandem Diabetes Care, Inc. (company) — Registrant
• May 10, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• San Diego, California (location) — Principal executive offices
• 001-36189 (company_id) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — ich Registered Common Stock, par value $0.001 per share TNDM NASDAQ Global Market I

Filing Documents

• tndm-20240510.htm (8-K) — 25KB
• 0001438133-24-000088.txt ( ) — 146KB
• tndm-20240510.xsd (EX-101.SCH) — 2KB
• tndm-20240510_lab.xml (EX-101.LAB) — 21KB
• tndm-20240510_pre.xml (EX-101.PRE) — 12KB
• tndm-20240510_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On May 10, 2024, Tandem Diabetes Care, Inc., a Delaware corporation (the "Company") and Unomedical a/s, a Danish corporation and a subsidiary of the ConvaTec Group ("Unomedical"), entered into Amendment Number 1 ("Amendment 1") to the Distributor Agreement, dated as of January 14, 2022, between the Company and Unomedical, under which Unomedical manufactures, tests, sterilizes and packs all of the infusion sets under the Company's brands (the "Original Agreement"). Under Amendment 1, the term of the Original Agreement is extended, and certain definitions and terms and conditions related to distributorship, additional products, manufacturing, labeling, product specifications, purchase commitments and other matters are amended. The foregoing description of Amendment 1 does not purport to be complete and is qualified in its entirety by reference to the full text of Amendment 1, which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the period ending June 30, 2024.

01 Other Events

Item 8.01 Other Events. On May 13, 2024, Health Canada approved the addition of Trurapi U-100 to the list of compatible insulins that can be used with the Company's t:slim X2 pump with Control-IQ technology in Canada.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Tandem Diabetes Care, Inc. By: /s/ SHANNON M. HANSEN Shannon M. Hansen Chief Legal, Privacy & Compliance Officer; Secretary Date: May 16, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR